Amarin Co. plc (NASDAQ:AMRN - Get Free Report)'s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $10.23 and traded as high as $11.34. Amarin shares last traded at $11.11, with a volume of 30,664 shares trading hands.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on the stock. The Goldman Sachs Group dropped their target price on shares of Amarin from $20.00 to $7.00 and set a "sell" rating on the stock in a research report on Thursday, April 17th. Wall Street Zen upgraded shares of Amarin from a "sell" rating to a "hold" rating in a research report on Thursday, May 8th.
Read Our Latest Research Report on Amarin
Amarin Stock Performance
The firm has a market cap of $235.23 million, a P/E ratio of -126.22 and a beta of 0.66. The stock's 50 day simple moving average is $9.82 and its 200 day simple moving average is $10.21.
Amarin (NASDAQ:AMRN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02. Amarin had a negative net margin of 16.33% and a negative return on equity of 7.22%. As a group, analysts forecast that Amarin Co. plc will post -0.15 EPS for the current fiscal year.
Institutional Trading of Amarin
A number of hedge funds and other institutional investors have recently bought and sold shares of AMRN. Banque Cantonale Vaudoise bought a new stake in shares of Amarin in the 1st quarter worth $25,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in shares of Amarin in the 4th quarter worth $36,000. Kornitzer Capital Management Inc. KS grew its stake in shares of Amarin by 4.0% in the 1st quarter. Kornitzer Capital Management Inc. KS now owns 88,200 shares of the biopharmaceutical company's stock worth $40,000 after acquiring an additional 3,400 shares in the last quarter. Generation Capital Management LLC bought a new stake in shares of Amarin in the 4th quarter worth $50,000. Finally, Stonepine Capital Management LLC bought a new stake in shares of Amarin in the 4th quarter worth $55,000. Institutional investors own 22.25% of the company's stock.
About Amarin
(
Get Free Report)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Read More
Before you consider Amarin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.
While Amarin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
